Compare HCA Health Inc (HCA) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Li Auto Inc — how do they compare? HCA Health Inc trades at $443.69 (market cap $96.35B), while Li Auto Inc trades at $11.31 (market cap $10.83B). The key difference: HCA Health Inc is far larger — about 8.9× Li Auto Inc's market cap, and HCA Health Inc pays a 0.7% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Li Auto Inc for 101 Days on average.
| HCA | LI | |
|---|---|---|
Market Cap | $96.35B | $10.83B |
Volume | 1,079,453 | 2,002,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $545.13 | $23.61 |
52-Week Low | $361.32 | $10.69 |
Typical Hold Time | 76 Days | 101 Days |
Enterprise Value | $146.88B | $258.87M |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
Li Auto (LI) trades at $10.99, down 0.92% on the day and near 52-week lows amid weak delivery numbers and earnings misses. The stock shows bearish technical signals with negative moving averages, though RSI indicates potential oversold conditions. Fundamentally, revenue declined to $112.31B in 2025 with net income margin turning negative at -4.4%, while valuation metrics show mixed signals with low P/S of 0.73 but high P/E of 99.38. Recent news highlights delivery moderation and new model launches as the company faces intense EV competition.
The outlook remains challenging with projected revenue decline to $104.8B and net loss of $4.6B in 2026. While analyst consensus suggests 38% upside to $15.18 price target, execution risks and cash burn pose significant headwinds. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of delivery recovery and margin improvement amid fierce Chinese EV competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
